Exactly two months ago I posted about US orphan oncology drug specialist, Pharmacyclics.
At the time, the company was capitalised at $9 billion, having grown from a market cap of $16 million in 2009.
Today it was announced that AbbVie has successfully outbid other pharmas, including Johnson & Johnson, to acquire Pharmacyclics.
The cost to AbbVie was $21 billion.
http://www.forbes.com/sites/bruceja...-21-billion-for-cancer-biotech-pharmacyclics/
A very expensive orphan....
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.25 |
Change
-0.400(2.93%) |
Mkt cap ! $1.696B | |||
| Open | High | Low | Value | Volume |
| $13.68 | $13.68 | $13.24 | $2.038M | 152.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 3698 | $13.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.26 | 1211 | 28 |
View Market Depth
| Last trade - 13.53pm 18/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |